TRIM21-dependent intracellular antibody neutralization of virus infection

Progress in Molecular Biology and Translational Science

Volumn 129, Issue , 2015, Pages 167-187

  McEwan, William A ^a   James, Leo C ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Antibody; Neutralization; TRIM21

Indexed keywords

BINDING PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN RECEPTOR; NEUTRALIZING ANTIBODY; PROTEASOME; TRIM21 PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN; UNCLASSIFIED DRUG; RIBONUCLEOPROTEIN;

ANTIGEN BINDING; CYTOKINE PRODUCTION; HUMAN; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WILD TYPE; ANIMAL; CHEMISTRY; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; HUMANS; INTRACELLULAR SPACE; NEUTRALIZATION TESTS; RIBONUCLEOPROTEINS; UBIQUITIN; VIRUS DISEASES;

EID: 84920918050     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2014.10.006     Document Type: Chapter

References (70)

1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401-409.
2. Moore ML, McKissic EL, Brown CC, Wilkinson JE, Spindler KR. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J Virol. 2004;78(11):5584-5590.
3. Han K, Lou DI, Sawyer SL. Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet. 2011;7(12):e1002388.
4. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO Jl. 2001;20(9):2140-2151.
5. Sanchez JG, Okreglicka K, Chandrasekaran V, Welker JM, Sundquist WI, Pornillos O. The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. Proc Natl Acad Sci USA. 2014;111(7):2494-2499.
6. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A. 2007;104(15):6200-6205.
7. Marin I. Origin and diversification of TRIM ubiquitin ligases. PLoS One. 2012;7(11):e50030.
8. Flajnik MF. Comparative analyses of immunoglobulin genes: surprises and portents. Nat Rev Immunol. 2002;2(9):688-698.
9. McEwan WA, Hauler F, Williams CR, Bidgood SR, Mallery DL, Crowther RA, et al. Regulation of virus neutralization and the persistent fraction by TRIM21. J Virol. 2012;86(16):8482-8491.
10. Chan EK, Hamel JC, Buyon JP, Tan EM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest. 1991;87(1):68-76.
11. Wahren-Herlenius M, Muller S, Isenberg D. Analysis of B-cell epitopes of the Ro/SS-A autoantigen. Immunol Today. 1999;20(5):234-240.
12. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA. 2010;107(46):19985-19990.
13. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA. 2008;105(16):6045-6050.
14. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14(4):327-336.
15. McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibodymediated immunity and the role of TRIM21. Bioessays. 2011;33(11):803-809.
16. Langford MP, Villarreal AL, Stanton GJ. Antibody and interferon act synergistically to inhibit enterovirus, adenovirus, and herpes simplex virus infection. Infect Immun. 1983;41(1):214-218.
17. Gallastegui N, Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem Sci. 2010;35(11):634-642.
18. Reddy VS, Natchiar SK, Stewart PL, Nemerow GR. Crystal structure of human adenovirus at 3.5 A resolution. Science. 2010;329(5995):1071-1075.
19. Zhang X, Shaw A, Bates PA, Newman RH, Gowen B, Orlova E, et al. Structure of the AAA ATPase p97. Mol Cell. 2000;6(6):1473-1484.
20. Isakov E, Stanhill A. Stalled proteasomes are directly relieved by P97 recruitment. J Biol Chem. 2011;286(35):30274-30283.
21. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012;14(2):117-123.
22. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci USA. 2011;108(12):4834-4839.
23. Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC. AAA ATPase p97/VCP is essential for TRIM21-mediated virus neutralization. Proc Natl Acad Sci USA. 2012;109(48):19733-19738.
24. Medzhitov R, Janeway Jr CA. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296(5566):298-300.
25. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
26. Watkinson RE, Tam JC, Vaysburd MJ, James LC. Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21. J Virol. 2013;87(13):7309-7313.
27. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe. 2012;12(5):633-644.
28. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472(7343):361-365.
29. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature. 2009;461(7260):114-119.
30. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006;22(2):245-257.
31. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol. 2006;8(4):398-406.
32. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2(9):706-713.
33. Watkinson RE, McEwan WA, James LC. Intracellular antibody immunity. J Clin Immunol. 2014;34(Suppl. 1):S30-S34.
34. Beuzon CR, Salcedo SP, Holden DW. Growth and killing of a Salmonella enterica serovar Typhimurium sifA mutant strain in the cytosol of different host cell lines. Microbiology. 2002;148(Pt. 9):2705-2715.
35. Birmingham CL, Brumell JH. Autophagy recognizes intracellular Salmonella enterica serovar Typhimurium in damaged vacuoles. Autophagy. 2006;2(3):156-158.
36. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320-1323.
37. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9(11):1408-1412.
38. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol. 1998;72(10):7909-7915.
39. Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, Hemmi S, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol. 2002;158(6):1119-1131.
40. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol. 2005;79(4):1992-2000.
41. Greber UF, Suomalainen M, Stidwill RP, Boucke K, Ebersold MW, Helenius A. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 1997;16(19):5998-6007.
42. Stuart AD, Brown TD. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J Virol. 2006;80(15):7500-7509.
43. Weiss VU, Subirats X, Pickl-Herk A, Bilek G, Winkler W, Kumar M, et al. Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas-phase electrophoretic mobility molecular analysis: part I. Electrophoresis. 2012;33(12):1833-1841.
44. Hewat EA, Neumann E, Blaas D. The concerted conformational changes during human rhinovirus 2 uncoating. Mol Cell. 2002;10(2):317-326.
45. Brabec-Zaruba M, Pfanzagl B, Blaas D, Fuchs R. Site of human rhinovirus RNA uncoating revealed by fluorescent in situ hybridization. J Virol. 2009;83(8):3770-3777.
46. Brabec M, Schober D, Wagner E, Bayer N, Murphy RF, Blaas D, et al. Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol. 2005;79(2):1008-1016.
47. Schober D, Kronenberger P, Prchla E, Blaas D, Fuchs R. Major and minor receptor group human rhinoviruses penetrate from endosomes by different mechanisms. J Virol. 1998;72(2):1354-1364.
48. Madan V, Sanz MA, Carrasco L. Requirement of the vesicular system for membrane permeabilization by Sindbis virus. Virology. 2005;332(1):307-315.
49. Dulbecco R, Vogt M, Strickland AG. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology. 1956;2(2):162-205.
50. Icenogle J, Shiwen H, Duke G, Gilbert S, Rueckert R, Anderegg J. Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology. 1983;127(2):412-425.
51. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol. 1988;62(7):2321-2328.
52. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. 2002;83(Pt. 9):2091-2108.
53. Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol. 2001;260:87-108.
54. Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol. 2004;78(22):12320-12332.
55. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol. 2001;77:195-262.
56. Magnus C, Regoes RR. Restricted occupancy models for neutralization of HIV virions and populations. J Theor Biol. 2011;283(1):192-202.
57. Kjellen L. A hypothesis accounting for the effect of the host cell on neutralization-resistant virus. J Gen Virol. 1985;66(Pt. 10):2279-2283.
58. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427(6977):848-853.
59. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA. 2006;103(19):7465-7470.
60. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. 2006;349(2):300-315.
61. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem. 2005;280(29):26933-26940.
62. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, et al. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol. 2009;83(20):10737-10751.
63. Campbell EM, Perez O, Anderson JL, Hope TJ. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 2008;180(3):549-561.
64. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, Yeager M. Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci USA. 2011;108(2):534-539.
65. Li X, Li Y, Stremlau M, Yuan W, Song B, Perron M, et al. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J Virol. 2006;80(13):6198-6206.
66. Chan E, Schaller T, Eddaoudi A, Zhan H, Tan CP, Jacobsen M, et al. Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor. Hum Gene Ther. 2012;23(11):1176-1185.
67. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology. 2007;369(2):400-410.
68. Shi J, Friedman DB, Aiken C. Retrovirus restriction by TRIM5 proteins requires recognition of only a small fraction of viral capsid subunits. J Virol. 2013;87(16):9271-9278.
69. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, et al. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol. 2013;87(1):257-272.
70. Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J, Shi M, et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity. 2013;38(2):384-398.